ClinicalTrials.gg
CompletedNCT03566316Updated Jun 25, 2018

Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

A Phase 3 interventional study of Telmisartan/Amlodipine and Rosuvastatin in Hypertension With Hyperlipidemia, sponsored by IlDong Pharmaceutical Co Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-06-25.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Nov 2015, registered Jun 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
134
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Hyperlipidemias with a site in Korea, Republic of — 3 open to participants now, 5 under way, 2 of them phase 3. Hyperlipidemias · Korea, Republic of.

Enrollment
33rd of 85
134 · median 80
Started
2015
with 7 others
Phase 3
27 of 89
1 open now
Registered
67th of 89
by date

Among the 89 studies in Hyperlipidemias with a site in Korea, Republic of, this one is the 33rd largest by enrollment of the 85 interventional ones that give a count, is one of 8 that started in 2015, is one of 27 in phase 3, and was the 67th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

3 of the 89 studies in Hyperlipidemias with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Hyperlipidemias with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients with Hyperlipidemia

03

Conditions studied

  • Hypertension With Hyperlipidemia
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19 years old or above
  2. Patients who confirmed essential hypertension with Hyperlipidemia or use of drugs at Visit 1 (sit systolic blood pressure ≥ 140mmHg, LDL-Cholesterol ≥ 100mg/dL)
  3. Patients who can stop the treatment of anti-hypertensive/anti-hyperlipidemic drugs in the opinion of the investigator
  4. Test results showing the following values at screening time (Visit 2) : sit systolic blood pressure >140mmHg
  5. Test results showing the following values at screening time (Visit 2) : 100\< LDL-Cholesterol \<250
  6. Patients who agreed to participate in the trial

Exclusion criteria

Exclusion Criteria:

  1. Severe hypertension patients(systolic blood pressure ≥ 180 mm Hg or diastolic blood pressure ≥ 110 mm Hg)

    -The change of mean sit systolic blood pressure ≥ 20 mmHg or sit diastolic blood pressure ≥ 10 mmHg on target arm between 1st and 2nd measurement

  2. LDL-Cholesterol > 250 mg/dL or triacylglycerol ≥ 400 mg/dL at screening time(Visit 1)
  3. Patients with postural hypotension who have sign and symptom
  4. Patients with secondary blood pressure(for example,aortic coarctation, hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, Polycystic Kidney Diseases)
  5. Patients with congestive heart failure( class III\~IV)
  6. Patients with history of acute coronary syndrome or underwent revascularization (percutaneous transluminal coronary angioplasty or Coronary Artery Bypass Graft surgery ) within 6 months
  7. Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter or arrhythmia
  8. Causes of hemodynamic disorder or structural heart defect such as valvular heart disease
  9. Patients who have history of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months prior to study entry
  10. Patients with primary aldosteronism
  11. Patients with severe ocular disorders
  12. Patients with disease
  13. Patients with any chronic inflammation disease needed to chronic inflammation therapy
  14. Patients with uncontrolled diabetes Mellitus with > 9% or thyroid diseases(TSH ≥ 1.5 X )
  15. Patients who have a history of myopathy or rhabdomyolysis
  16. Patients who have 3 times of upper limit of normal range of muscle enzyme (creatinine kinase, CK)
  17. History of malignant tumor including leukemia, lymphoma within 5 years
  18. Patients with one kidney
  19. Patients with biliary obstructive disorder
  20. Patients with clinically significant electrolyte disturbance
  21. Continued serum potassium concentration abnormal status (\<3.5mEq/L or >5.5mEq/L)
  22. Patients with sodium ion or body fluid is depleted and not able to correct
  23. Patients with clinically significant liver/renal disease
  24. Patients with digestive diseases that may affect the absorption or history in gastrointestinal surgery
  25. Patients who are dependent on drugs or alcohol
  26. Pregnancy, breast-feeding, or Patients
  27. Patients with to telmisartan or other angiotensin II receptor blockers
  28. Patients with hypersensitivity to Amlodipine or other dihydropyridine drugs
  29. Patients with history of Myotoxicity to other 3-hydroxy-methyl glutaryl-coenzyme A reductase inhibitor or fibrate
  30. Patients who are unable to stop taking prohibited drugs to combination during study period
  31. Patients who have galactose intolerance
  32. Patients taking other clinical trial drugs within 30 days from the time of visit for screening
  33. Patients that is not eligible to participate at the discretion of study investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
134 participants (actual)

Study arms

  • Experimental
    Telmisartan/Amlodipine+Rosuvastatin

    Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin 20mg1tab. and Telmisartan placebo 1tab.

    Drug: Telmisartan/Amlodipine · Drug: Rosuvastatin

  • Active comparator
    Telmisartan/Amlodipine

    Telmisartan/Amlodipine 40/5mg 2tab., Rosuvastatin placebo 1tab. and Telmisartan placebo 1tab.

    Drug: Telmisartan/Amlodipine

  • Active comparator
    Telmisartan +Rosuvastatin

    Telmisartan/Amlodipine placebo 2tab., Rosuvastatin 80mg 1tab. and Telmisartan 20mg 1tab.

    Drug: Rosuvastatin · Drug: Telmisartan

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of change in LDL-Cholesterol

    Telmisartan/Amlodipine/Rosuvastatin versus Telmisartan/Amlodipine

    Time frame: From baseline at week 8

  2. The change of sitting systolic blood pressure

    Telmisartan/Amlodipine/Rosuvastatin versus Telmisartan/Rosuvastatin

    Time frame: From baseline at week 8

Secondary outcomes

  1. Percentage of change in LDL-Cholesterol

    Time frame: From baseline at week 4

  2. Percentage of change in HDL-Cholesterol, total Cholesterol, Triglyceride, Apolipoprotein B

    Time frame: From baseline at week 4 and 8

  3. The change of HDL-Cholesterol/LDL-Cholesterol ratio

    Time frame: From baseline at week 4 and 8

  4. The change of total cholesterol/HDL-Cholesterol ratio

    Time frame: From baseline at week 4 and 8

  5. Percentage of patients reaching treatment goals according to National Cholesterol Education Program-Adults Treatment Panel III Guideline

    Time frame: From baseline at week 4 and 8

  6. The change of sitting diastolic blood pressure

    Time frame: From baseline at week 4 and 8

  7. Percentage of patients reaching treatment goals according to Joint National Committee VIII Guideline

    Time frame: From baseline at week 4 and 8

07

Study locations

1 site
  • Korea University Guro Hospital
    Seoul, Korea, Republic of
08

References and documents

Publications

  • Kim TS, Rha SW, Kim SY, Park DG, Sung KC, Yoon MH, Kim KH, Lee HC, Kim WS, Kim YJ, Ahn JC, Rhee MY, Cha DH, Yoo BS, Park SH, Yoo KD, Jeon DW, Yoon YW, Cho SK, Oh YS. Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study. Clin Ther. 2019 Apr;41(4):728-741. doi: 10.1016/j.clinthera.2019.02.013. Epub 2019 Mar 21. PubMed 30904178 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Jun 2017, 18 months.

Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2018
First posted
Jun 25, 2018
StartActual
Nov 24, 2015
Primary completionActual
Jun 16, 2017
CompletionActual
Jun 16, 2017
Last update
Jun 25, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03566316
Responsible party
Sponsor
First posted
Jun 25, 2018
Start date
Nov 24, 2015
Primary completion
Jun 16, 2017
Completion
Jun 16, 2017
Last update
Jun 25, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Telmisartan · Amlodipine · Rosuvastatin

Start the discussion